격투스포츠 선수의 스포츠맨십 분석

박태훈(Park Tae-Hoon),유기성(Yoo Ki-Seong),유원용(Ryu Won-Yong),김영욱(Kim Young-Wook),이양구(Lee Yang-Gu),공창빈(Kong Chang-Bin),이상호(Lee Sang-Ho),김태영(Kim Tae-Young) 한국체육과학회 2010 한국체육과학회지 Vol.19 No.3

This research examines whether difference that is some in inclination of combat sports player's sportsmanship is, and accordingly is purposeful to clear relation. combat sports (fencing, Taekwondo, boxing, induction, wrestling, wrestling) player who research target is having player life in middle·high·an university 399 people be . Used Korean-made measure (KMSOS) that Seong-changhun (2003) verifies changing based on Vallerand MSOS by a tool to measure sportsmanship of players. Data processing used SPSS 12.0 programs. Did reliability analysis that use Cronbach'a coefficient to verify believability of an irradiation tool, Difference of sportsmanship used t-test, one-way ANOVA. In this research, drew following conclusion. First, man appeared higher level than woman in wave and human desire, decision respect, and woman appeared higher level than man in victory or defeat excessive fondness. Second, exercise immersion, decision respect, victory or defeat excessive fondness appeared level that minority is taller than majority. Third, in exercise immersion high school player decision respect appear, and tendency of level that middle school playing the first stone is high in victory or defeat excessive fondness appeared. Fourth, striking radical type of player appeared higher level than Geuraepeulring type of player in companion respect factor. Fifth, player less than exercise career 4 years appeared higher level than player less than 7 years and player more than 7 years for victory or defeat excessive fondness factor. Sixth, Taekwondo for best and companion respect factor, high level appeared to boxing item players.

류마티스성 승모판 협착증의 치료를 위한 경피적 승모판 성형술의 치료성적

김성은,조흥근,박성훈,박시훈 梨花女子大學校 醫科大學 醫科學硏究所 1999 EMJ (Ewha medical journal) Vol.22 No.4

연구목적 : 류마티스성 승모판 협착증에 대한 유용한 치료법인 경피적 승모판 성형술의 본원의 단기 치료 성적을 알아보고자 하였다. 방법: 1993년 10월에서 1999년 4월까지의 이대목동병원에 내원한 류마티스성 승모판 협착증 환자 21명에서 투시조명 하에 경피적 승모판 성형술을 시행하였다. 시술전에 경흥부심초음파와 경식도초음파가 시행되었고, 시술후에는 경흉부초음파를 사용하여 혈역학적, 임상학적 변화를 비교하였다. 연구대상의 거의 모두가 NYHA class Ⅱ에 속했고, 5명이 심방세동을 가지고 있었으며, 모두 심초음파점수가 8이하였다. 좌심방에 혈전이 있는 경우로 혈전을 용해시킨 후 시술한 경우가 2예였다. 결과 : 경피적 승모판 성형술 이후의 평균 승모판구면적은 시술전의 1.16±0.36㎠에서 2.06±0.33㎠로 증가되었다. 경승모판 이완기 평균 압력차는 시술전 11.60±5.54mmHg에서 시술 후 4.93±2.53mmHg(p<0.001). 좌심방 크기는 46.41±14.66mm에서 42.03±15.01mm로(p=0.042), 그리고 심박출량은 4.21±1.25L/min에서 6.88±9.57L/min로(p<0.0001) 의미있는 호전을 보였다. 3도 이상의 심한 승모관폐쇄부전이나 심각한 시술후 합병증은 없었다. 결론 : 본원에서 약 6년간 시행된 경피적 승모판 성형술는 그 사례가 적고 시술전 예상되는 난이도 면에서 특이한 것은 없었지만, 시술후 합병증이 거의 발견되지 않았으며 혈역학적 측정상에서도 성공적인 시술을 보여주었다. 승모판구면적에 따른 시술후 단기내 호전의 정도는 거의 예측할 수 없었으나, 심초음파점수는 모두가 8점이하로 높은 성공율의 조건을 제공하였다. Objective : Percutaneous mitral valvuloplasty(PMV) became a treatment modality or mitral stenosis because of its low morbidity, short hospital stay, and low cost. We reviewed clinical and hemodynamic results after PMV for the patients with mitral stenosis in Ewha Womans University Mokdong hospital. Methods : We compared the results of echocardiographic, hemodynamic, and clinical parameters before and after PMV. PMV was performed under fluoroscopic guidance in 21 patients(M:4, F:17, mean age 43±12 years) with mitral stenosis from October 1993 to April 1999. Transesophageal echocardiography(TEE) and Transthoracic echocardiography(TTE) were performed for the evaluation of mitral valve, chamber size, and the presence of left atrial thrombus before procedures. TIE was also used for follow-up evaluation. On presentation, all patients showed at least NYHA class Ⅱ. Five patients had atrial fibrillation. Two patients with thrombus in the left atrium were included to study group after thrombolytic treatment with coumadin. Echo-score of our patients was not greater than 8. Results : Mean mitral valve area(MVA) by 2 dimensional or Doppler echocardiography was increased from 1.16±0.36㎠ before PMV to 2.06±0.33㎠ after PMV. There were marked improvements in transmitral gradients(11.60±5.54mmHg before PMV vs 4.93±2.53mmHg after PMV, p<0.001), left atrial dimension(46.41±14.66mm vs 42.03±15.01mm, p=0.042), and cardiac output(4.21±1.25L/min vs 6.88±9.57L/min, p<0.0001) following PMV, Severe(≥GⅢ) mitral insufficiency or severe postprocedural complications were not noted. This suggested that all procedure was successful. Conclusion : The Procedural success rate of PMV in Ewha Womans University Mokdong hospital was 100%. Low echo score of our patients might explain this high procedural success rate. Long-term-follow-up is warranted in the near future.

정보화사회의 새로운 패러다임 Ubiquitous Computing 에 관한연구

박성훈 서강전문대학 지역발전연구소 2003 지역발전연구 : 서강전문대 Vol.9 No.-

당귀와 천궁 및 시호의 병용 경구 투여에서 흰쥐 혈중 Decursinol 농도의 비교 검토

박노정,김남재,이경태,서성훈 경희대학교 동서의학연구소 2001 東西醫學硏究所 論文集 Vol.2001 No.-

This study was performed to elucidate the influence on the plasma decursinol concentration after administration of combined decursin and Cnidii Rhizoma or decurisin and Bupleuri Radix extracts in comparison with single decursin admimistration. The identification of decursional isolated from Angelica gigas was carried out by GC/MS and the concentration of decursinol in the plasma after oral administration was determined by HPLC. The value of area under the plasma concentration (AUC) and the maximal concentration (Cmas) of decursinol after administration of methanol and ether Angelicae Gigantis Radix extract was higher than those of single decursin-treated group. It was also found that the AUC and the Cmax of decursional after combined administration with decursin and Cnidii Rhizoma were higher than those of decursin administration, whereas those of combined with decursin and Bupleuri Radix was lower. Moreover, the studies were performed with decursinol only or with combined decursinol and Cnidii Rhizoma/Bupleuri Radix, both of combined treatment increased the plasma decursinol concentrations compared with decursinol-treated group in rats. On the basis of these results, it is concluded that co-existing substances or co-administration with other drugs may influence the plasma levels of decurisinol after oral administration.

급성 신부전증을 초래한 Wegener씨 육아종증 1례

박일,임영국,최성도,임현성,정종훈,문철웅 朝鮮大學校 附設 醫學硏究所 1992 The Medical Journal of Chosun University Vol.17 No.1

호흡기 증상과 급성신부전증이 발생된 환자에서 혈액검사, 혈청학적 검사, 방사선학적 검사, ANCA test 및 신생검을 통하여 Wegener씨 육아종증을 경험하였기에 문헌 고찰과 함께 보고하는 바이다. 본질환이 재발하는 경우는 cyclophosphamide에서 azathioprine으로 치료약을 바꾸었을때나 특히 ANCA 반응이 양성으로 지속시 발생한다. Godman과 Churg는 상기도의 괴사성 육아성 병변, 하기도의 괴사성 혈관염, 국한성 신사구체염을 진단의 지표로 삼았다. 특히 상기도 점막의 생검 소견상 괴사성 육아성 혈관염이 보이면 일단 본 증을 의심하고 폐 생검과 신 생검이 필요로 한다. Wegener's Granulomatosis is an uncommon disease which is characterized by granulomatous vasculitis of both lung and kidney. Although the cause is unknown, it's suggesting that disordered immunity with both antibody and cell-mediated tissue damage occurs. The disease affects patients of any age. Characteristic clinical manifestations are diverse but in clude saddle nose deformity, sinusitis, productive coughing, myalgia, fever etc. Characteristic laboratory abnormalities include elevated ESR, neutrophilic leukocytosis, anemia and positive test for ANCA test. Renal biopsy is important for diagnosis. The treatment of choice is a combination of corticosteroid and cytotoxic agent. A53-year-old woman was admitted to our hospital because of productive coughing, short of breathing, oliguria, nausea, and vomiting. Three months ago, she was suffered from general weakness, poor appetite, tingling sensation on extremity, and loosely stool. Twenty days ago, above symptoms were aggravated, she admitted local clinic. Six days ago, because of CBC showed anemia , she was done transfusion. During transfusion, she was developed urticaha then productive coughing, dyspnea, increased serum BUN and creatinine levels. She was transferred to our hospital under the impression of ARF. On the admission, she was chronic ill-looking appearance with pale conjunctiva, tachypnea, dyspnea, and cold sweating. We have checked the patient by CBC, serum and serologic test, X-ray, ANCA test, renal biopsy. With renal biopsy microscopic examination study revealed necrotizing vasculitis, We treated a combination therapy with methyl-PDS and cyclophosphamide. She had a good response. So we report wegener's granulomatosis with the review of relevant literature.

고콜레스테롤 혈증 환자에서 Cerivastatin(LIPOBAY, 의과학연구소)의 임상효과 및 안전성에 관한 연구

박성훈,김미연,정수진,이영숙,박창한,변은경,전성희 梨花女子大學校 醫科大學 醫科學硏究所 2001 EMJ (Ewha medical journal) Vol.24 No.3

목적 : Cerivastatin(LIPOBAY)은 최근에 개발되어 사용되기 시작한 HMG-CoA 환원효소 억제제로서 저용량으로 탁월한 콜레스테롤 강하효과를 보이는 약물이다. 저자들은 Cerivatatin(LIPOBAY)의 혈중 콜레스테롤 강하효과를 평가하고 약물의 안전성을 평가하기 위하여 본 연구를 시행하였다. 방법 : 고콜레스테롤혈증 환자 37명(남자 13명, 여자 24명)을 대상으로 하였다. 대상환자는 2주간의 저콜레스테롤 식이 후에도 혈청 콜레스테롤이 240㎎/㎗이상이거나, 관상동맥질환이 있는 환자는 혈청콜레스테롤이 220㎎/㎗이상인 경우 cerivastatin 0.4㎎을 8주간 복용하도록 하였다. 임상적 관찰과 검사실 검사(간기능검사, 일반혈액검사, 혈청지질검사)는 투약개시 후 4주 및 8주 후에 시행하였다. 결과 : Cerivastatin 0.4㎎을 4주간 투여한 후 측정한 LDL 콜레스테롤, 총콜레스테롤, triglyceride, 및 HDL 콜레스테롤은 각각 38%, 28.8%, 11.6% 및 7.8% 감소하였다. 총콜레스테롤/HDL 콜레스테롤 비 및 LDL/HDL비는 각각 20.8% 및 31.1% 감소하였다. 투약 8주후에 측정한 검사소견은 4주후에 비해 유의한 변화를 보이지 않았다. 한명의 환자(2.7%)에서 간기능 검사상 AST, 및 ALT의 지속적인 상승으로 투약을 중지하였다. 결론 : Cerivastatin 0.4㎎/day는 혈청콜레스테롤을 효과적으로 감소시켰으며 심각한 부작용은 볼 수 없었다. 따라서 적극적으로 LDL콜레스테롤을 낮출 필요가 있는 고콜레스테롤혈증 환자에서 cerivastatin은 효과적이고 안전한 약물이라고 생각된다. Objectives : Cerivastain(LIPOBAY) is recently developed HMG-CoA reductase inhibitor which is effective in lowering serum cholesterol levels at microgram does. We evaluated the clinical efficacy and safety of cerivastatin(LIPOBAY) in patients with hypercholesterolemia. Method : Thirty-seven patients(male : 13, female : 24) with hypercholesteolemia defined as baseline serum total cholesterol ≥240㎎/㎗, or ≥220㎎/㎗ in patients with known coronary artery disease were included for this study. After 2 weeks of low cholesterol diet, if the serum total choesterol level meet the criteria, cerivastain 0.4㎎/day was prescribed for 8 weeks. Clinical follow-up and laboratory tests were performed 4 weeks and 8 weeks after medication. Results : After 4 weeks of cerivastain 0.4㎎/day treatment, low density lipoprotein(LDL) cholesterol decreased 38% and total cholesterol decreased 28.8% from baseline. Triglyceride decreased 11.6%, and high density lipoprotein(HDL) cholesterol decreased 7.8% from baseline. Total cholesterol/HDL ratio decreased 20.8% and LDL/HDL ratio decreased 31.1% from baseline. After 8 weeks of treatment, no further significant changes were noted compared with the values at 4 weeks. Cervastatin was discontinued in one patient(2.7%) due to continuous liver enzyme elevation. Conclusion : Cerivastatin 0.4㎎/day is effective in lowering serum cholesterol levels without significant adverse reactions. Cerivastatin is effective and safe for patients with hypercholesterolemia who needs aggressive LDL cholesterol lowering.

당귀와 천궁 및 시호의 병용 경구 투여에서 흰쥐 혈중 Decursinol 농도의 비교 검토

박노정,김남재,이경태,서성훈 경희대학교 경희동서약학연구소 2001 경희약대 논문집 Vol.29 No.-

This study was performed to elucidate the influence on the plasma decursinol concentration after administration of combined decursin and Cnidii Rhizoma or decurisin and Bupleuri Radix extracts in comparison with single decursin administration. The identification of decursinol in the plasma after oral administration was determined by HPLC. The value of area under the plasma concentration (AUC) and the maximal concentration (Cmax) of decursinol after administration of methanol and ether Angelicae Gigantis Radix extract was higher than those of single decursin-treated group. It was also found that the AUC and the Cmax of decursinol after combined administration with decursin and Cnidii Rhizoma were higher than those of decursin administration, whereas those of combined with decursin and Bupleuri Radix was lower. Moreover, the studies were performed with decursinol only or with combined decursinol and Cnidii Rhizoma/Bupleuri Radix, both of combined treatment increased the plasma decursinol concentrations compared with decursinol-treated group in rats. On the basis of these results, it is concluded that co-existing substances or co-administration with other drugs may influence the plasma levels of decurisinol after oral administration.

Losartan(Cozaar®)의 강압효과에 관한 임상적 연구

박성훈,박영미 梨花女子大學校 醫科大學 醫科學硏究所 1999 EMJ (Ewha medical journal) Vol.22 No.4

연구배경 : 로자탄은 angiotensin Ⅱ수용체들 중 AT, 수용체를 선택적으로 차단함으로써 혈압강하효과를 나타내며, 마른 기침이나 혈관부종과 같은 ACE차단제의 부작용이 거의 없다. 방법 : 로자탄 50mg/day를 제1기 및 제2기의 고혈압환자 22명(남자:12명, 여자:10명, 평균 나이:51±11세, 나이분포:33±70세)의 환자에게 12주간 투여하여 약제의 혈압강하효과 및 안전성을 평가하였다. 결과 : 혈압은 투약후 2주부터 하강하기 시작하여 6주에 최대강하를 보였다. 6주와 12주 사이의 혈압변동은 통계적 유의성은 없었다. 12주에 측정한 평균혈압은 로자탄 투여전에 비해 수축기혈압이 19mmHg, 이완기 혈압이 11mmHg 하강하였다. 로자탄 투여후 심각한 임상적 또는 검사상의 부작용은 발생하지 않았으며, 부작용으로 인하여 투약을 중단한 예도 없었다. 결론 : 로자탄(Cozaar®)은 제1단계 및 제2단계 고혈압에 대한 1일 1회 단독치료제로서의 안전하고 효과적인 혈압강하제로 생각된다. Background : Although angiotensin converting enzyme inhibitors have provided plausible effect for the management of hypertension and congestive heart failure, it does have drawbacks such as dry cough in as much as 15 to 30% of patients and incomplete blocking of angiotensin Ⅱ production. Losartan(Cozaar®) is the first angiotensin Ⅱ receptor antagonist that has become clinically available as an antihypertensive agent. Because the agent effectively blocks the final common pathway of renin-angiotensin system, it is recognized as an ideal drug for the treatment of hypertension. Method : We tested the antihypertensive effect and clinical safety of Losartan(Cozaar®) 50mg/day in 22 patients(male : 12, female : 10, age : 51±11, range : 33-70) with stage I and Ⅱ hypertension from July 1998 to October 1999. The patients were enrolled in the study after two weeks of washout period if the patient was using other antihypertensive drugs. Blood pressure and side effects were monitored at zero, second, sixth, and twelfth week. Baseline chemistry was done before drug administration and follow-up chemistry was done at twelfth week. Results : Losartan(Cozaar®) showed good patient compliance and good antihypertensive effect without significant changes of laboratory results or clinical complications. At twelfth week, mean systolic blood pressure dropped l9mmHg, and mean diastolic blood pressure dropped 11㎜Hg. The heart rate showed no significant change during the study period. Blood pressure was controlled below 140/90mmHg in 12(54.5%) patients with Losartan 50mg/day. Five patients complained of minor side effects(dizziness, facial numbness, epigastric discomfort, etc) but no patients discontinued medication due to side effects. Conclusion : Losartan(Cozaar®) is a safe and effective antihypertensive agent for the treatment of stage Ⅰ and Ⅱ hypertensive patients as a single once-a-day treatment.

역학적 자료에 기초한 수축기 혈압과 맥압의 중요성

박성훈 대한간질학회 2003 대한간질학회지 Vol.9 No.1

경식도심초음파가이드를 이용한 승모판풍선성형술

박성훈,김명아,현민수 대한순환기학회 1997 Korean Circulation Journal Vol.27 No.7